#1 Clinical Trials Search in Europe

Lerodalcibep

Lerodalcibep, also known as LIB003 or HST101, is an investigational drug being studied in clinical trials for its potential to lower cholesterol levels in patients with various cardiovascular conditions. This article explores the ongoing research on lerodalcibep, focusing on its efficacy, safety, and potential benefits for patients with high cholesterol, including those with familial hypercholesterolemia and cardiovascular disease.

Table of Contents

What is Lerodalcibep?

Lerodalcibep, also known as LIB003 or HST101, is a new medication being developed to treat high cholesterol levels in the blood[1][2][7]. It belongs to a class of drugs called PCSK9 inhibitors, which are designed to lower low-density lipoprotein cholesterol (LDL-C), often referred to as “bad cholesterol”[6].

How Does Lerodalcibep Work?

Lerodalcibep works by targeting a protein in the body called PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9). This protein normally helps regulate the amount of LDL cholesterol in your blood. By inhibiting PCSK9, lerodalcibep allows the body to remove more LDL cholesterol from the bloodstream, resulting in lower cholesterol levels[3].

What Conditions Does Lerodalcibep Treat?

Lerodalcibep is being studied to treat several conditions related to high cholesterol:

  • Cardiovascular Disease (CVD): This includes conditions affecting the heart and blood vessels, such as heart disease and stroke[1][2].
  • Hypercholesterolemia: A condition characterized by high levels of cholesterol in the blood[4].
  • Familial Hypercholesterolemia (FH): An inherited condition that leads to extremely high cholesterol levels. This includes:
    • Heterozygous Familial Hypercholesterolemia (HeFH): Where a person inherits the condition from one parent[3].
    • Homozygous Familial Hypercholesterolemia (HoFH): A rare and severe form where a person inherits the condition from both parents[6].

How is Lerodalcibep Administered?

Lerodalcibep is administered as a subcutaneous injection (an injection under the skin) once every four weeks (monthly). The typical dose being studied is 300 mg[1][2]. In some studies, patients or caregivers may be able to administer the medication at home after proper training[1].

How Effective is Lerodalcibep?

The effectiveness of lerodalcibep is still being studied in clinical trials. Researchers are looking at how well it lowers LDL cholesterol levels compared to a placebo (a substance with no active medication) or other cholesterol-lowering drugs. Some key points about its effectiveness include:

  • It’s being studied for its ability to lower LDL cholesterol levels over periods of 24 to 52 weeks[2][5].
  • Researchers are also looking at how many patients can achieve recommended cholesterol goals while taking lerodalcibep[2].
  • In addition to LDL cholesterol, studies are examining its effects on other types of fats in the blood, such as triglycerides and high-density lipoprotein (HDL) cholesterol[7].

Safety and Side Effects

As with all medications, researchers are carefully monitoring the safety of lerodalcibep. This includes:

  • Tracking the occurrence and severity of side effects, known as adverse events[1][2].
  • Monitoring for any allergic reactions to the medication, including the development of antibodies against the drug[6].
  • Evaluating any reactions at the injection site[7].

It’s important to note that as lerodalcibep is still in clinical trials, not all potential side effects may be known yet. Patients participating in these trials are closely monitored by healthcare professionals.

Ongoing Research

Lerodalcibep is currently being studied in several Phase 3 clinical trials. These are large-scale studies designed to confirm the effectiveness and safety of the medication before it can be approved for general use. Some of the ongoing research includes:

  • Long-term studies lasting up to 72 weeks to evaluate the safety and effectiveness of lerodalcibep over extended periods[1].
  • Comparisons with other cholesterol-lowering medications, such as evolocumab (Repatha®), another PCSK9 inhibitor[6].
  • Studies specifically focused on patients with familial hypercholesterolemia[3][6].
  • Research on how well the medication works in different populations, including a study specifically for Chinese patients[7].

These ongoing studies will help determine if lerodalcibep is safe and effective enough to become an approved treatment option for patients with high cholesterol and related conditions.

Aspect Details
Drug Name Lerodalcibep (also known as LIB003 or HST101)
Drug Class PCSK9 inhibitor
Administration 300 mg subcutaneous injection every 4 weeks (Q4W)
Target Conditions Hypercholesterolemia, Cardiovascular Disease, Familial Hypercholesterolemia (HeFH and HoFH)
Primary Outcomes LDL-C reduction, Safety and tolerability
Secondary Outcomes Changes in free PCSK9, other lipid parameters, achievement of LDL-C goals
Trial Durations 24 to 72 weeks
Trial Designs Randomized, double-blind, placebo-controlled, and open-label extension studies
Comparators Placebo, Evolocumab (in some trials)

FAQ

  • What is lerodalcibep and how does it work? Lerodalcibep is a PCSK9 inhibitor, a type of drug that helps lower LDL (bad) cholesterol levels in the blood. It works by blocking the PCSK9 protein, which normally reduces the liver's ability to remove LDL cholesterol from the bloodstream. By inhibiting PCSK9, lerodalcibep allows the liver to remove more LDL cholesterol, resulting in lower cholesterol levels.
  • Who might benefit from lerodalcibep treatment? Based on the clinical trials, lerodalcibep is being studied in patients with various conditions related to high cholesterol, including those with cardiovascular disease (CVD), heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and patients at high risk for CVD who require additional LDL cholesterol reduction despite being on stable lipid-lowering therapy.
  • How is lerodalcibep administered? Lerodalcibep is administered as a subcutaneous (under the skin) injection, typically given once every four weeks (Q4W) at a dose of 300 mg. In clinical trials, it is being compared to placebo or other cholesterol-lowering medications like evolocumab.
  • What are the primary outcomes being measured in lerodalcibep clinical trials? The main outcomes being assessed in lerodalcibep trials include the percent reduction in LDL cholesterol levels compared to placebo or baseline, changes in other lipid parameters (such as free PCSK9 levels), and the safety and tolerability of the drug as measured by the incidence of treatment-emergent adverse events.
  • How long do the clinical trials for lerodalcibep typically last? The duration of lerodalcibep clinical trials varies, but many of the Phase 3 studies last between 24 to 72 weeks. Some trials include an initial double-blind period followed by an open-label extension phase to assess long-term efficacy and safety.

Ongoing Clinical Trials on Lerodalcibep

  • Lerodalcibep for Heterozygous Familial Hypercholesterolemia in Children and Adolescents 6 to 17 Years Old

    Not yet recruiting

    1 1
    Investigated drugs:
    Norway

  • Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Norway Spain

Glossary

  • PCSK9 inhibitor: A type of cholesterol-lowering medication that blocks the action of PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the blood.
  • LDL-C: Low-Density Lipoprotein Cholesterol, often referred to as 'bad' cholesterol. High levels of LDL-C in the blood can contribute to the buildup of plaque in arteries, increasing the risk of heart disease and stroke.
  • Familial Hypercholesterolemia (FH): An inherited condition characterized by very high levels of LDL cholesterol from birth. It can be heterozygous (HeFH) when inherited from one parent or homozygous (HoFH) when inherited from both parents, with HoFH being more severe.
  • Cardiovascular Disease (CVD): A group of disorders affecting the heart and blood vessels, often associated with the buildup of fatty deposits in the arteries (atherosclerosis).
  • Subcutaneous (SC): Referring to the layer of tissue just beneath the skin. In the context of medication administration, it means an injection given into this tissue layer.
  • Q4W: An abbreviation meaning 'every 4 weeks,' used to describe the frequency of drug administration.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active ingredient. It's used as a control in clinical trials to help determine the true effects of the investigational drug.
  • Open-label: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the active drug and who is receiving the placebo or comparator drug.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

References

  1. https://clinicaltrials.eu/trial/study-on-long-term-effects-of-lerodalcibep-for-lowering-cholesterol-in-patients-with-familial-hypercholesterolemia-or-cardiovascular-disease-risks/
  2. https://clinicaltrials.gov/study/NCT04797247
  3. https://clinicaltrials.gov/study/NCT04797104
  4. https://clinicaltrials.gov/study/NCT05234775
  5. https://clinicaltrials.gov/study/NCT04806893
  6. https://clinicaltrials.gov/study/NCT04034485
  7. https://clinicaltrials.gov/study/NCT06568471